Study: Alzheimer's Drug for Medicare Patients Could Cost U.S. at Least $2B Annually

Wide coverage of Alzheimer's drug Leqembi would raise future costs for Medicare by at least $2 billion a year, according to a study led by University of California researchers.

Related Keywords

United States ,San Diego ,California ,Americans , ,Biogen Inc ,Reuters ,Medicaid Services ,University Towne Center ,Centers For Medicare ,Eisai Co Ltd ,San Diego Idec Pharmaceuticals ,Drug Administration ,Biogen Elsai Medicare ,Idec Pharmaceuticals ,Nobel Campus ,Julia Cave Arbanas ,John Mafi ,